PRAME (PReferentially-expressed Antigen in MElanoma) is an autosomal cancer-testis antigen (CTA) gene that encodes a 509 amino acid residue protein which is associated with the outcome and risk of metastasis. It is a melanoma antigen that is preferentially expressed in tumours and is recognized by cytotoxic T lymphocytes. PRAME is expressed in melanoma cells, various non-melanocytic malignant neoplasms, including non-small cell lung cancer, breast carcinoma, renal cell carcinoma, ovarian carcinoma, Hodgkin’s disease, leukaemia, synovial sarcoma, multiple myeloma and myxoid liposarcoma. PRAME is not strongly expressed in most other normal tissues except for testis, ovary, placenta, adrenals, and endometrium.
Intended Use: IVD
Antibody Type: Monoclonal
Clone: PRAME/8558R
Source: Rabbit
Tissue Type/Cancer Type: Testis, Melanoma tissue